Patents
Literature
8 results about "Cellulose acetate phthalate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cellulose acetate phthalate (CAP), also known as cellacefate (INN) and cellulosi acetas phthalas, is a commonly used polymer phthalate in the formulation of pharmaceuticals, such as the enteric coating of tablets or capsules and for controlled release formulations. It is a cellulose polymer where about half of the hydroxyls are esterified with acetyls, a quarter are esterified with one or two carboxyls of a phthalic acid, and the remainder are unchanged. It is a hygroscopic white to off-white free-flowing powder, granules, or flakes. It is tasteless and odorless, though may have a weak odor of acetic acid. Its main use in pharmaceutics is with enteric formulations. It can be used together with other coating agents, e.g. ethyl cellulose. Cellulose acetate phthalate is commonly plasticized with diethyl phthalate, a hydrophobic compound, or triethyl citrate, a hydrophilic compound; other compatible plasticizers are various phthalates, triacetin, dibutyl tartrate, glycerol, propylene glycol, tripropionin, triacetin citrate, acetylated monoglycerides, etc.
Biodegradable Fuse-Reservoir System for Intermittent Delivery of Bioactive Agents
PendingJP2025539925ANervous disorderSynthetic resin layered productsCellulose acetate phthalateActive agent
A device for delivering one or more bioactive agents is disclosed. The device comprises: a first layer comprising a first biodegradable polymer, the first layer having a first side and a second side, with a plurality of reservoirs containing one or more bioactive agents present on the first side; a second layer comprising a second biodegradable polymer adjacent to the first side of the first layer; and a third layer comprising a third biodegradable polymer, the third layer sealing the first and second layers and including an exposed second layer where at least one surface of the device is not covered by the third biodegradable polymer. In one embodiment, the first and third biodegradable polymers are poly-ε-caprolactone, and the second biodegradable polymer is a mixture of cellulose acetate phthalate and poloxamer. A method for manufacturing the device is also disclosed.
Owner:UNIVERSITY OF MISSISSIPPI
Stomach-passing acid-resistant intestinal slow-release coating preparation as well as preparation method and application thereof
PendingCN120531065AAccessory food factorsWorking-up animal fodderCellulose acetateIntestino-intestinal
The invention relates to the technical field of coating preparations, and particularly discloses a stomach-passing acid-resistant intestinal slow-release coating preparation as well as a preparation method and application thereof. The coating preparation is prepared from 15 to 30 parts of polyacrylic resin III, 10 to 20 parts of hydroxypropyl methyl cellulose phthalate, 10 to 20 parts of cellulose acetate phthalate, 20 to 50 parts of absolute ethyl alcohol, 5 to 20 parts of methanol and 15 to 30 parts of acetone. Mixing polyacrylic resin III with absolute ethyl alcohol to form a swelling substance; mixing the hydroxypropyl methyl cellulose with the phthalate and a mixture of methanol and acetone to form a swelled substance; mixing cellulose acetate phthalate with acetone to form a swelling substance; and uniformly mixing the three swelling substances to obtain the stomach-passing acid-resistant intestinal slow-release coating preparation. The prepared coating preparation has the advantages of good coating effect, good stomach passing effect and high small intestine release rate, the mechanical parameters of the obtained coating film are reasonable, and the bridging phenomenon of the coating particles is avoided.
Owner:JIANGSU AOMAI BIOLOGICAL SCI & TECH CO LTD
Solid dispersion, preparation method, and pharmaceutical composition thereof
The present invention provides a solid dispersion comprising lurasidone or a pharmaceutically acceptable salt thereof and a carrier. The carrier material includes polyvinyl acetate phthalate (PVAP), polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), mesoporous silica, hydroxypropyl methylcellulose (HPMC), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, acrylic resin, hydroxypropyl cellulose (HPC), povidone, copovidone, ethylcellulose, polyoxyethylene glycol, hypromellose acetate succinate (HPMCAS), hypromellose phthalate (HPMCP), or a combination thereof.
Owner:ANXO PHARMA CO LTD
System for the manufacture of a Pulsincap dosage form containing lovastatin and colesevelam for the treatment of hypercholesterolemia
A system for manufacturing a Pulsincap dosage form containing lovastatin and colesevelam for the treatment of hypercholesterolemia, comprising: a) a fungal cultivation facility configured to cultivate mangrove-associated marine fungi from the group consisting of Aspergillus sp., Penicillium sp., Rhizophus sp. and Fusarium sp. in production media to produce the metabolite lovastatin; b) a microsphere preparation plant for the production of floating lovastatin microspheres using ionotropic gelation technology with chitosan, sodium alginate and calcium carbonate; c) a granulation plant for the production of colesevelam granules using explosives from the group consisting of croscarmellose and microcrystalline cellulose; d) a capsule coating unit configured to coat the capsule body with cellulose acetate phthalate (CAP); and e) a stopper preparation unit configured to prepare hydrogel stoppers and coat them with ethylcellulose.
Owner:AMEEN MANHA ROCKVILLE +9
Budesonide enteric capsule and preparation method thereof
PendingCN121313605AHydroxy compound active ingredientsDigestive systemCelluloseSustained release pellets
The invention provides a budesonide enteric capsule, which is characterized in that resveratrol is used as a pellet core, budesonide, zein, hydroxypropyl methylcellulose acetate succinate, polyvinylpyrrolidone, acetyl triethyl citrate and tween-80 are used for preparing a budesonide sustained-release pellet, and the budesonide enteric capsule is prepared from the budesonide, the zein, the hydroxypropyl methylcellulose acetate succinate, the polyvinylpyrrolidone, the acetyl triethyl citrate and the tween-80. Cellulose acetate phthalate and zinc pectin are adopted to prepare the budesonide enteric-coated sustained-release pellet, and the budesonide enteric-coated capsule prepared through filling has the enteric-coated characteristic, and the effect is better than that of single use of cellulose acetate phthalate or zinc pectin as an enteric-coated material; and the budesonide enteric capsule prepared by taking resveratrol as the pellet core has better ulcerative colitis treatment effect than the budesonide enteric capsule prepared by taking cane sugar as the pellet core.
Owner:CHANGZHOU NO 4 PHARMA FACTORY +1
Amorphous nilotinib oral soluble film preparation and preparation method thereof
PendingCN121081426AOrganic active ingredientsPharmaceutical non-active ingredientsCellulosePolyvinyl alcohol
The invention discloses an amorphous nilotinib oral soluble film preparation and a preparation method thereof. The amorphous nilotinib oral soluble film preparation is prepared from the following raw and auxiliary materials in percentage by mass: 0.1-30% of nilotinib, 1-40% of an enteric polymer material, 30-70% of a film-forming agent and 5-40% of a plasticizer, the enteric polymer material is one or more of hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinyl alcohol phthalate acetate, cellulose trimellitate acetate, cellulose acetate phthalate, acrylic resin EuS100 and acrylic resin EuL100. According to the oral soluble film preparation disclosed by the invention, the saturation solubility of nilotinib in an environment with the pH value being greater than 4.5 is remarkably improved, the dissolution and absorption of a nilotinib medicine in an intestinal environment are increased, the bioavailability is improved, the administration dosage is further reduced, the administration requirements of children are met, the food effect and toxic and side effects are reduced, and the administration safety of patients is improved.
Owner:NEOFORM BIOPHARMACEUTICAL LTD
Wood frog egg peptide microsphere preparation with enteric protection and preparation method of wood frog egg peptide microsphere preparation
The invention discloses a wood frog egg peptide microsphere preparation with enteric protection and a preparation method of the wood frog egg peptide microsphere preparation, and belongs to the technical field of pharmaceutical preparations. The preparation comprises wood frog egg peptide subjected to antigen removal treatment, a biodegradable polymer (polylactic acid-glycolic acid copolymer, polylactic acid or chitosan), an enteric-coated material (acrylic resin, hydroxypropyl methylcellulose phthalate or cellulose acetate phthalate) and an additive, and the mass ratio of the wood frog egg peptide to the biodegradable polymer is 1: (2-10). The dosage of the enteric-coated material is 5-20% of the total mass of the microspheres. The preparation method comprises the following steps: carrying out enzymolysis, ultrafiltration, gel chromatography purification and antigen removal treatment (affinity chromatography / chemical modification / ultrafiltration combined with gel chromatography) on wood frog egg peptide; preparing microspheres through an improved single emulsion-solvent evaporation method; and coating an enteric-coated material. The preparation disclosed by the invention is stable in drug release, high in bioavailability, low in immunogenicity, simple and controllable in preparation process and sustainable in raw material, and is suitable for enteric preparation application of wood frog egg peptide bioactive substances.
Owner:HANGZHOU FUBANG MEDICAL TECH CO LTD
Solid dispersions, methods of preparation, and pharmaceutical compositions thereof
Some embodiments of the present disclosure provide solid dispersions comprising lurasidone, or a pharmaceutically acceptable salt thereof, and a carrier. The carrier is prepared from the following materials: polyvinyl acetate phthalate (PVAP), polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), mesoporous silicon oxide, hydroxypropyl methyl cellulose (HPMC), a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol grafted copolymer, acrylic resin, hydroxypropyl cellulose (HPC), polyvinylpyrrolidone, copovidone and ethyl cellulose; the composition may be selected from the group consisting of hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol, hydroxypropyl methyl cellulose succinate (HPMCAS), hydroxypropyl methyl cellulose phthalate (HPMCP), or a combination thereof.
Owner:ANXO PHARMA CO LTD